| 產(chǎn)品編號 | bs-12980R |
| 英文名稱 | Rabbit Anti-phospho-DAP Kinase 2 (Ser318) antibody |
| 中文名稱 | 磷酸化凋亡相關(guān)蛋白激酶2抗體 |
| 別 名 | DAP Kinase 2 (phospho S318); p-DAP Kinase 2 (phospho S318); Death associated protein kinase 2; DAK 2; DAK2; DAP kinase related protein 1; DAPK 2; DAPK2; Death associated protein kinase 2; DRP 1; DRP1; DRP-1; MGC119312; DAP kinase 2; DAP kinase related protein 1; DAP kinase related protein 1 beta isoform; DAP-kinase-related protein 1; DAPK 2; DAPK2; DAPK2_HUMAN; Death associated protein kinase 2; Death-associated protein kinase 2; DRP 1; DRP-1; DRP1; MGC119312. |
| 產(chǎn)品類型 | 磷酸化抗體 |
| 研究領(lǐng)域 | 細胞生物 信號轉(zhuǎn)導(dǎo) 細胞凋亡 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human,Mouse,Rat,Rabbit,Pig,Sheep,Cow,Dog,GuineaPig,Horse) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500,ICC/IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 41kDa |
| 細胞定位 | 細胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human DAP Kinase 2 around the phosphorylation site of Ser318: KL(p-S)FS |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Protein kinase termed (DAPK2) dependant on calcium/calmodulin (Ca2+/CaM) contains an N-terminal protein kinase domain followed by a conserved CaM-binding domain with significant homologies to those of DAP kinase, a protein kinase involved in apoptosis. Overexpression of DAPK2 significantly induced the morphological changes characteristic of apoptosis. Results indicate that DAPK2 is an additional member of DAP kinase family involved in apoptotic signaling. Function: Functions in mitochondrial and peroxisomal division. Mediates membrane fission through oligomerization into ring-like structures which wrap around the scission site to constict and sever the mitochondrial membrane through a GTP hydrolysis-dependent mechanism. Required for normal brain development. Facilitates developmentally-regulated apoptosis during neural tube development. Required for a normal rate of cytochrome c release and caspase activation during apoptosis. Also required for mitochondrial fission during mitosis. May be involved in vesicle transport. Isoform 1 and isoform 4 inhibit peroxisomal division when overexpressed. Subunit: Homodimer in its autoinhibited state. Active as monomer. Isoform 2 but not isoform 1 can interact with ATF4. Subcellular Location: Cytoplasm. Cytoplasmic vesicle, autophagosome lumen. Tissue Specificity: Ubiquitously expressed with highest levels found in skeletal muscles, heart, kidney and brain. Isoform 1 is brain-specific. Isoform 2 and isoform 3 are predominantly expressed in testis and skeletal muscles respectively. Isoform 4 is weakly expressed in brain, heart and kidney. Isoform 5 is dominantly expressed in liver, heart and kidney. Isoform 6 is expressed in neurons. Post-translational modifications: Autophosphorylation at Ser-318 inhibits its catalytic activity. Dephosphorylated at Ser-318 in response to activated Fas and TNF-alpha receptors. Similarity: Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. DAP kinase subfamily. Contains 1 protein kinase domain. SWISS: Q9UIK4 Gene ID: 23604 Database links: Entrez Gene: 23604 Human Entrez Gene: 13143 Mouse Omim: 604727 Human SwissProt: Q9UIK4 Human SwissProt: Q8VDF3 Mouse Unigene: 237886 Human Unigene: 304472 Mouse Unigene: 335252 Mouse Unigene: 98325 Rat |
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
